PTC Therapeutics, Inc. (PTCT) fair value analysis
Nasdaq · Updated 2026-09-07
PTC Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes medicines for rare genetic disorders and oncology. The company operates globally with a focus on bringing treatments to patients in North America, Europe, and other international markets.
Valuation status
Awaiting full valuationPTCT does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $68.11
- Sector
- Healthcare
- 12-month range
- $62.01–$81.35
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Low
- RSI zone
- Neutral
- 50/200-day trend
- Mixed
- 52-week position
- The lower-middle quarter of its range
What our data shows for PTCT
- Our model validated 4 trailing price-to-earnings windows for PTCT, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $62.01–$81.35.
- The 14-day relative strength index sits at a neutral 48.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for PTCT
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent PTCT news
TickrTrends' derived news-sentiment signal for PTCT is currently leaning positive, computed from recent coverage.
- PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential (NASDAQ:PTCT) (seekingalpha.com, 2026-08-24)
TickrTrends take: PTC Therapeutics operates in the Healthcare sector, where acquisition activity can significantly impact valuation frameworks. With TickrTrends currently awaiting full valuation context for PTCT, investors focused on valuation metrics should monitor how any acquisition developments might influence the company's financial profile and comparable trading multiples. The timing and structure of potential M&A activity will be important factors for establishing a more complete valuation assessment. - PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript (seekingalpha.com, 2026-08-13)
TickrTrends take: PTC Therapeutics announced an acquisition of ST-920, a Fabry gene therapy asset, along with clinical data from the STAAR study, which represents a strategic expansion of its pipeline in a rare disease indication. For investors monitoring valuation, the clinical efficacy data from STAAR will be critical to assess whether this acquisition adds meaningful value to the company's portfolio and justifies the associated costs. TickrTrends is currently awaiting full valuation metrics on PTCT, making near-term clarity on ST-920's commercial potential and development timeline important factors for establishing a comprehensive valuation framework.
What people are saying
Follow the PTCT conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is PTCT stock undervalued?
PTCT does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is PTCT's TickrTrends verdict?
PTCT is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is PTCT overbought or oversold?
PTCT's 14-day RSI is in neutral territory - neither overbought nor oversold.